Related Experiment Video
Updated: Aug 14, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Docetaxel administered every two weeks as second-line chemotherapy for advanced non-small cell lung cancer: a phase
Luigi De Petris1, Maria Rita Migliorino, Anna Ceribelli
15th Pneumo-Oncology Unit, Department of Oncology, S. Camillo-Forlanini Hospitals, V. Portuense 332, 00149 Rome, Italy.
Background:
The aim of this phase II study was to evaluate efficacy and toxicity of single-agent docetaxel, administered every two weeks as second-line treatment for patients with recurrent non-small cell lung cancer (NSCLC).
Patients And Methods:
Forty-eight patients with confirmed NSCLC were enrolled in this trial The median age was 56.5 years (range 43-76), median PS was 1, and the main histology type was adenocarcinoma (54%). Only 8% of patients had previously received paclitaxel. Patients received docetaxel i.v., 50 mg/m2 over 1 hour, on day 1 every 2 weeks.
Results:
The overall response rate was 8.3% (95% Confidence Interval 0.5-161%). The median time to disease progression, median survival time and 1-year survival rate were 3 months, 6 months and 21%, respectively. Grade 3-4 neutropenia was registered in 47% of patients, with only 1 patient (2%) experiencing febrile neutropenia. Nonhematological toxicity was mild (grade 1-2) and consisted mainly of asthenia (19%o) and diarrhea (10%).
Conclusion:
The bi-weekly schedule of docetaxel showed an activity comparable to the standard tri-weekly 75 mg/m2 schedule as second-line treatment for recurrent NSCLC. Though non-hematological toxicity is significantly reduced, myelosuppression is still a matter of concern.
